NEW ORLEANS — Odronextamab showed promising efficacy among patients with grade 1 to grade 3a follicular lymphoma who received two or more prior lines of therapy, according to study results presented at ASH Annual Meeting and Exposition.Three-quarters of patients in the cohort achieved complete remission with the hinge-stabilized, human immunoglobulin G4-based CD20 x CD3 bispecific antibody,